DDInter1664 DDInter927
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Sevoflurane {u} (Compound) resembles {v} (Compound) Perflutren
Sevoflurane {u} (Compound) binds {v} (Gene) GABRP
Sevoflurane {u} (Compound) is included by {v} (Pharmacologic Class) General Anesthesia
Sevoflurane {u} (Compound) causes {v} (Side Effect) Obstructive airways disorder
Sevoflurane {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Sevoflurane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Sevoflurane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Granisetron
Sevoflurane {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Sevoflurane {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Sevoflurane (Compound) resembles Perflutren (Compound)
Sevoflurane (Compound) binds GABRP (Gene)
Sevoflurane (Compound) is included by General Anesthesia (Pharmacologic Class)
Sevoflurane (Compound) causes Obstructive airways disorder (Side Effect)
Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Sevoflurane may lead to a major life threatening interaction when taken with Halofantrine
Sevoflurane may lead to a major life threatening interaction when taken with Pasireotide